Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

The goal of this clinical trial is to test the safety of the trifluridine/tipiracil as replacement of fluoropyrimidines based chemotherapy as first line metastatic colorectal or gastroesophageal cancer regimens in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. The main questions it aims to answer are: * Is this alternative chemotherapy option a better option in term of safety for this type of patients? * Does the combination of treatments improves the overall safety? * Does the combination of treatments improves the progression-free survival, overall survival, objective resp

Trial Details

NCT ID
NCT06245356
Phase
PHASE2
Sponsor
UNICANCER
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Lonsurf
  • Oxaliplatin
  • Panitumumab
  • Bevacizumab
  • Trastuzumab
  • Nivolumab
Locations (sample)
  • Amiens, France|49.9,2.3
  • Angers, France|47.47156,-0.55202
  • Avignon, France|43.94834,4.80892
  • Besançon, France|47.24878,6.01815
  • Cholet, France|47.05893,-0.87974

Key Eligibility Criteria

  • Patient must have signed and dated a written informed consent form prior to any trial specific procedures. When the patient is physically unable to…
  • Histological or cytological documentation of adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower oesophagus, gastroesophageal j…
  • Synchronous or metachronous metastatic colorectal or gastroesophageal cancer
  • Presence of at least one measurable lesion according to RECIST v1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →